Novartis Sues Alvogen To Block Generic Dementia Patch

By Ben James (January 7, 2013, 7:54 PM EST) -- Novartis AG slapped generic-drug maker Alvogen Group Inc. with a lawsuit in Delaware on Friday, accusing Alvogen of infringing two patents by seeking U.S. regulatory approval to make and sell generic versions of the Exelon patch, a dementia treatment.

Patent co-owners Novartis and LTS Lohmann Therapie-Systeme AG targeted Alvogen and a Pine Brook, N.J.-based Alvogen subsidiary, asking the court to rule that Alvogen had infringed the patent-in-suit and order that the approval of Alvogen's bid for approval of its proposed rivastigmine transdermal products can't come before the plaintiffs' patent rights expire.

The abbreviated new drug application that Alvogen submitted to the...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!